Zegalogue Autoinjector (Dasiglucagon HCl) Patent Expiration, LOE Window & CMS Spending

Zegalogue Autoinjector (Dasiglucagon HCl) by Novo Nordisk: FDA Orange Book core substance LOE 2035-03-22, 0 AB generics, $1.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovo Nordisk
FDA Application & PathwayN214231 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2035-03-22
Last Listed Patent or Exclusivity Date2035-03-22
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.2M
2024 Medicare Part D Spend$184K
2024 Medicaid Spend$1.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.